Candel Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Candel Therapeutics, Inc. filed a Form 8-K dated November 15, 2023, reporting a Nasdaq continued-listing deficiency. The company’s common stock trades under the symbol CADL on The Nasdaq Global Market.
Material event
Nasdaq notified the company that CADL’s closing bid price had remained below the required minimum of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The notice did not immediately affect the stock’s listing or trading status.
- The initial compliance period expires May 13, 2024.
- The company can regain compliance if its bid price closes at or above $1.00 for at least 10 consecutive business days before the deadline.
- If necessary, Nasdaq may grant a second 180-day compliance period, generally requiring transfer to the Nasdaq Capital Market and satisfaction of applicable initial listing standards other than the bid-price requirement.
- If the company fails to regain compliance and does not qualify for an additional period, Nasdaq may begin delisting proceedings.
- The company may appeal a delisting determination to the Nasdaq Listing Qualifications Panel, although success is not assured.
Financial metrics and liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Guidance, outlook, risks, and unusual items
Management stated that it intends to monitor the closing bid price and may consider available measures to regain compliance. The filing provides no specific remediation plan and no assurance that compliance will be restored. Potential consequences include transfer to another Nasdaq market, delisting, reduced liquidity, and adverse effects on the company’s stock price and access to capital.
Important facts for investors to verify
- Whether CADL regained the $1.00 minimum bid-price requirement by May 13, 2024.
- Whether Nasdaq granted a second compliance period or required a market transfer.
- Any subsequent Nasdaq delisting notice, appeal, reverse stock split, or other corporate action.
- The company’s financial condition, cash runway, financing needs, and operating results in subsequent filings, which are not addressed in this Form 8-K.